Related to Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models

• EU Speeds Approval of Novartis’ mAb for CAPS in Adults and Children
  
• Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Astex Signs CRADA with NCI to Investigate Its Small Molecule Therapeutic
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Germany Sanctions Novartis’ Cell Culture-Based H1N1 Flu Vaccine
  
• Boehringer Ingelheim Pledges $22.5M to Fund Another Four Years of Partnership with Evotec
  
• Gene Pinpointed that Could Negate Cancer Cells’ Ability to Repair Themselves
  
• Novartis’ Swine Flu Vaccine Effective at Half the Current Antigen Dose
  
• Targeting a Tumor’s Microenvironment Could Be Used to Treat Cancer
  
• Amgen to Apply ImmunoGen TAP Technology to Another Cancer Target
  
• Novartis Inaugurates $1B U.S. Cell Culture Flu Vaccine Facility
  
• Quantum Immunologics to Commercialize Auburn University’s Veterinary Cancer Immunotherapy
  
• Minerva Grants Clarient Exclusive Rights to Develop MUC1* Biomarker for Cancer Diagnostics
  
• Forma Pockets $25.5M to Advance Cancer Drug Discovery Activities
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• EU Sanctions Novartis’ Once-Daily Inhaled Therapy for COPD
  
• Pfizer and Crown Team Up to Develop Treatments for Asian Cancers
  
• Researchers Provide Systems-Level Dissection of Regulatory Perturbations in Cancer
  
• Ludwig Institute to Evaluate Pro-Pharmaceuticals’ Candidate for Its Ability to Enhance Antitumor T Cells